Breaking News Instant updates and real-time market news.

INCY

Incyte

$78.05

-0.47 (-0.60%)

10:47
10/16/19
10/16
10:47
10/16/19
10:47

Incyte REACH2 'a nice win,' data should be presented at ASH, says Piper Jaffray

Piper Jaffray analyst Tyler Van Buren notes that Incyte announced that REACH2, which is evaluating Jakafi in steroid-refractory acute GvHD, "nicely" met its primary response rate-based endpoint and he believes the data could be presented at ASH. Further, the company disclosed that the REACH3 trial is continuing as planned after an interim efficacy and safety review by the data monitoring committee, although the analyst estimates the data is now delayed until Q3 of 2020. Therefore, by year-end, the remaining major GvHD catalyst is the GRAVITAS-301 trial, which will likely come in December, Van Buren points out, adding that he believes should be a success. While the delay is "slightly frustrating," the analyst still finds the broader REACH2+3 update to be "encouraging" for the overall GvHD franchise, which could generate $500M-plus in sales by 2025. He has an Overweight rating and $95 price target.

  • 29

    Oct

  • 06

    Nov

INCY Incyte
$78.05

-0.47 (-0.60%)

10/02/19
MZHO
10/02/19
INITIATION
Target $95
MZHO
Buy
Incyte initiated with a Buy at Mizuho
Mizuho analyst Mara Goldstein started Incyte with a Buy rating and $95 price target. Continued growth of the base business provides "solid" cash flow now while the company builds toward revenue diversification, Goldstein tells investors in a research note. The analyst views Incyte shares as being "lower-risk given modest pipeline expectations" and sees a "compelling" changing product mix going forward.
10/03/19
10/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Incyte (INCY) initiated with a Buy at Mizuho. 2. Lyft (LYFT) and Uber (UBER) initiated with a Neutral at MKM Partners. 3. Arrowhead (ARWR) initiated with an Outperform at Baird. 4. United Technologies (UTX) initiated with an Outperform at Credit Suisse. 5. Ulta Beauty (ULTA) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/14/19
PIPR
10/14/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte data enchances confidence in $500M opportunity, says Piper Jaffray
Incyte over the weekend reported 52-week follow-up data for the Phase II topical ruxolitinib study in vitiligo patients. Previously, Incyte reported positive 24-week data, which included significant improvements in F-VASI75 scores, with deeper responses for a considerable proportion of patients, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. This weekend's update demonstrated that topical ruxolitinib continues to be well tolerated and that patients achieved sustained and/or deeper responses at 52 weeks as the number of patients achieving F-VASI75 increased to 52% from 30% at 24 weeks, says the analyst. The data enhance his confidence that topical ruxolitinib is providing "meaningful and durable" clinical benefit to patients that otherwise do not have treatment options. He believes vitiligo could conservatively represent a $500M-plus sales opportunity. Van Buren keeps an Overweight rating on Incyte with a $95 price target.

TODAY'S FREE FLY STORIES

07:50
11/15/19
11/15
07:50
11/15/19
07:50
Conference/Events
The Brookings Institution to hold a discussion »

Brookings hosts a…

ROKU

Roku

$148.70

6.32 (4.44%)

, WMT

Walmart

$120.65

-0.41 (-0.34%)

07:49
11/15/19
11/15
07:49
11/15/19
07:49
Recommendations
Roku, Walmart analyst commentary  »

Roku price target raised…

ROKU

Roku

$148.70

6.32 (4.44%)

WMT

Walmart

$120.65

-0.41 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

SLS

Sellas Life Sciences

$6.20

0.01 (0.16%)

07:49
11/15/19
11/15
07:49
11/15/19
07:49
Upgrade
Sellas Life Sciences rating change  »

Sellas Life Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

07:49
11/15/19
11/15
07:49
11/15/19
07:49
Conference/Events
JMP Securities to hold a bus tour »

Medical Devices &…

DHR

Danaher

$136.16

-0.89 (-0.65%)

07:47
11/15/19
11/15
07:47
11/15/19
07:47
Conference/Events
Danaher management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CGC

Canopy Growth

$15.84

-2.68 (-14.47%)

07:46
11/15/19
11/15
07:46
11/15/19
07:46
Downgrade
Canopy Growth rating change  »

Canopy Growth downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

EBIX

Ebix

$32.80

-3.6 (-9.89%)

07:46
11/15/19
11/15
07:46
11/15/19
07:46
Hot Stocks
Ebix says offer accepted by Committee of Creditors for Trimax IT assets »

Ebix announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CY

Cypress Semiconductor

$23.43

0.01 (0.04%)

07:45
11/15/19
11/15
07:45
11/15/19
07:45
Downgrade
Cypress Semiconductor rating change  »

Cypress Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$120.65

-0.41 (-0.34%)

07:44
11/15/19
11/15
07:44
11/15/19
07:44
Recommendations
Walmart analyst commentary  »

Walmart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHNG

Change Healthcare

$13.91

0.74 (5.62%)

07:43
11/15/19
11/15
07:43
11/15/19
07:43
Conference/Events
Change Healthcare management to meet with SunTrust »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

BGNE

BeiGene

$195.90

-1.25 (-0.63%)

, AZN

AstraZeneca

$47.37

-0.47 (-0.98%)

07:43
11/15/19
11/15
07:43
11/15/19
07:43
Recommendations
BeiGene, AstraZeneca, AbbVie analyst commentary  »

BeiGene price target…

BGNE

BeiGene

$195.90

-1.25 (-0.63%)

AZN

AstraZeneca

$47.37

-0.47 (-0.98%)

ABBV

AbbVie

$87.61

0.94 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

  • 27

    Feb

LPTX

Leap Therapeutics

$0.57

-0.5922 (-50.83%)

07:43
11/15/19
11/15
07:43
11/15/19
07:43
Downgrade
Leap Therapeutics rating change  »

Raymond James cuts Leap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$209.88

1.33 (0.64%)

07:42
11/15/19
11/15
07:42
11/15/19
07:42
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

DFS

Discover

$84.76

0.42 (0.50%)

07:41
11/15/19
11/15
07:41
11/15/19
07:41
Hot Stocks
Discover reports October net charge-off rate 3.27% vs. 3.32% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:41
11/15/19
11/15
07:41
11/15/19
07:41
Hot Stocks
Auxly Cannabis announces launch of Robinsons Outdoor Grow cultivation project »

Auxly Cannabis Group,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$15.84

-2.68 (-14.47%)

, ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

07:40
11/15/19
11/15
07:40
11/15/19
07:40
Recommendations
Canopy Growth, Aurora Cannabis analyst commentary  »

Canopy Growth, Aurora…

CGC

Canopy Growth

$15.84

-2.68 (-14.47%)

ACB

Aurora Cannabis

$3.29

-0.25 (-7.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

07:40
11/15/19
11/15
07:40
11/15/19
07:40
General news
Treasury Market Outlook: yields are a little cheaper »

Treasury Market Outlook:…

NVDA

Nvidia

$209.88

1.33 (0.64%)

07:39
11/15/19
11/15
07:39
11/15/19
07:39
Recommendations
Nvidia analyst commentary  »

Nvidia data center…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 06

    Jan

GDS

GDS Holdings

$44.55

1.61 (3.75%)

07:39
11/15/19
11/15
07:39
11/15/19
07:39
Recommendations
GDS Holdings analyst commentary  »

GDS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ARWR

Arrowhead

$48.51

-0.06 (-0.12%)

07:39
11/15/19
11/15
07:39
11/15/19
07:39
Hot Stocks
Arrowhead announces COO Bruce Given to retire, names new CMO and CSO »

Arrowhead announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

CEMI

Chembio Diagnostics

$4.31

0.3 (7.48%)

07:38
11/15/19
11/15
07:38
11/15/19
07:38
Conference/Events
Chembio Diagnostics management to meet with Craig-Hallum »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

SYF

Synchrony

$36.71

0.145 (0.40%)

07:38
11/15/19
11/15
07:38
11/15/19
07:38
Hot Stocks
Synchrony reports October net charge-off rate 3.54% vs. 3.84% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$128.68

0.19 (0.15%)

07:38
11/15/19
11/15
07:38
11/15/19
07:38
Hot Stocks
JPMorgan reports October net credit loss 1.61% vs. 2.32% last month »

Reports October 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 14

    Jan

PRPL

Purple Innovation

$7.50

0.465 (6.61%)

07:38
11/15/19
11/15
07:38
11/15/19
07:38
Syndicate
Purple Innovation 10M share Secondary priced at $7.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

COF

Capital One

$96.64

0.31 (0.32%)

07:37
11/15/19
11/15
07:37
11/15/19
07:37
Hot Stocks
Capital One reports October net charge-offs 3.95% vs. 4.25% last year »

Reports 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.